HER-2 and choice of adjuvant chemotherapy in breast cancer.
The amplification or overexpression of HER-2 is a recognized prognostic marker that is associated with poor survival for patients with node-positive breast cancer. Several studies have demonstrated that HER-2 may serve to direct the selection of optimal adjuvant chemotherapy. This article provides a critical review of the studies that offer evidence for the role of HER-2 as a predictor of response to chemotherapy.